Quercetin Research Overview (also known as Quercetin aglycone, 3,3′,4′,5,7-pentahydroxyflavone, Sophoretin)
Quercetin is a naturally occurring flavonoid polyphenol found in foods such as onions, apples, berries, and capers. It is studied for antioxidant, anti-inflammatory, vascular, and potential senolytic activity, including its use in experimental combinations with dasatinib to investigate the selective removal of senescent cells.
What Is Quercetin?
Quercetin is a flavonol, a subclass of flavonoid polyphenols produced by many plants. It is present in onions, apples, berries, tea, leafy vegetables, capers, and other foods, usually as glycoside conjugates in which a sugar is attached to the quercetin molecule. Commercial research preparations commonly contain quercetin aglycone or formulated derivatives intended to improve dissolution and absorption. Quercetin is not a peptide, hormone, or approved senolytic drug; it is a nutritional small molecule used in laboratory, animal, and human translational research.
Interest in quercetin within longevity research comes from several overlapping properties. In cell and animal models, it can influence redox balance, inflammatory transcription, kinase signaling, mitochondrial responses, endothelial biology, and pathways associated with cellular senescence. Quercetin has also been investigated as one component of the dasatinib-plus-quercetin senolytic combination, often abbreviated D+Q. Evidence for these effects depends strongly on dose, formulation, tissue distribution, disease model, and exposure duration. Findings from concentrated supplements should not be assumed to reproduce the effects of dietary quercetin or to establish a clinically validated anti-aging treatment.
Research Indications
Cardiometabolic Markers
Blood pressure
Small controlled human studies, particularly in people with elevated blood pressure, have reported modest reductions in systolic blood pressure with quercetin supplementation.
Endothelial and vascular function
Research supports effects on oxidative signaling and endothelial function, although clinical findings differ by population, dose, and formulation.
Inflammatory and Oxidative Stress Pathways
Inflammatory biomarkers
Trials and meta-analyses have examined C-reactive protein and cytokine outcomes, but results are heterogeneous and do not establish a treatment role.
Antioxidant-response signaling
Cell and animal work shows modulation of redox-sensitive pathways; direct translation of these mechanisms to clinical benefit remains uncertain.
Healthy Aging and Cellular Resilience
Senescence-related pathways
Preclinical studies have investigated quercetin in combination with other flavonoids for senescence-related biology; human longevity outcomes have not been established.
Exercise recovery and immune stress
Human exercise studies have explored illness incidence and immune markers, with mixed findings that require replication in broader populations.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General dietary-flavonoid research | 250 mg | Once daily | Oral |
| Cardiometabolic studies | 500 mg | Once daily | Oral |
| Exercise and immune-stress protocols | 500–1,000 mg | Daily, divided or single dose | Oral |
| Short-term higher-dose research | 1,000 mg | Once daily | Oral |
Timing
Oral quercetin is commonly taken with food to improve tolerability. Formulation materially affects absorption; research products may use aglycone, glycoside, phytosome, or other enhanced-bioavailability forms, which should not be assumed interchangeable.
Peptide Interactions
These flavonoids are jointly investigated in preclinical senescence-related research. Human efficacy and long-term safety of combination protocols remain unproven.
Vitamin C and quercetin frequently co-occur in dietary and supplement formulations; evidence for a clinically meaningful combined effect is limited.
Both are polyphenols with overlapping research interests. No established direct interaction is known, though multi-ingredient products can complicate tolerability assessment.
Quercetin may influence platelet-related pathways and drug metabolism. Individuals using anticoagulant or antiplatelet therapy should seek clinician guidance before supplementation.
In vitro and pharmacokinetic data suggest potential effects on transporters and metabolizing enzymes. Medication-specific interaction risk should be reviewed by a pharmacist or prescriber.
Because quercetin is studied for metabolic effects, people using glucose-lowering drugs should monitor for changes in glucose control with their treating clinician.
Reported Research Timeline
01First dose to 24 hours (reported in cited studies): most people notice no acute subjective effect. Mild gastrointestinal upset or headache, if it occurs, is more likely to appear early.
02Days 2–7 (reported in cited studies): assess tolerability, including digestion, sleep, skin reactions, and any changes relevant to concurrent medications.
03Weeks 2–4 (reported in cited studies): controlled studies evaluating biomarkers commonly use regular daily dosing over several weeks; subjective benefits are not a reliable measure of biological effect.
04Weeks 4–8 (reported in cited studies): this is a typical window for reassessing a research-style trial using objective measures such as blood pressure, where clinically appropriate.
05Weeks 8–12 (reported in cited studies): published intervention durations often fall in this range. Any continued use should account for medication changes, laboratory findings, and adverse effects.
06Beyond 12 weeks: long-term high-dose safety and durable longevity outcomes remain insufficiently established; periodic reassessment is prudent.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Oral quercetin is generally studied short-term, but supplement formulations and absorbed doses vary substantially.
Potential mild effects include nausea, abdominal discomfort, headache, or tingling; take with food if gastrointestinal symptoms occur.
Avoid assuming that enhanced-bioavailability products have the same safety profile as standard quercetin powder at an identical label dose.
Use caution with prescription medicines, especially drugs with narrow therapeutic ranges or medicines affected by transporter and enzyme activity.
Pregnant or breastfeeding individuals, children, and people with significant liver or kidney disease should obtain clinician advice before use.
Seek Medical Attention If:
You develop signs of a severe allergic reaction, including facial or throat swelling, wheezing, hives, or difficulty breathing.
You experience unusual bleeding, black stools, vomiting blood, or extensive unexplained bruising.
You develop severe or persistent abdominal pain, repeated vomiting, fainting, or symptoms of markedly low blood pressure.
You notice jaundice, dark urine, severe fatigue, or other symptoms suggesting a possible liver-related problem.
Quality Indicators
Verified Marker
Batch-specific certificate of analysis
Look for a lot-number-matched COA reporting identity and assay results for the finished quercetin ingredient or finished capsule batch.
Verified Marker
HPLC or equivalent purity assay
A credible product provides chromatographic purity testing and identifies whether the material is quercetin aglycone or a specified quercetin complex.
Verified Marker
Independent contaminant testing
Prefer third-party testing for heavy metals and relevant microbiological contaminants, with results that can be tied to the product lot.
Acceptable Range
Accurate capsule labeling
The label should clearly state milligrams of actual quercetin per capsule and distinguish active compound from a proprietary blend or delivery complex.
Quality Concern
Unverifiable purity or dose claims
Avoid products without a batch COA, with implausibly broad health claims, or that fail to disclose the quercetin form and actual milligram content.
Research Citations
- Quercetin reduces systolic blood pressure in hypertensive subjects.
Egert, S., Bosy-Westphal, A., Seiberl, J., et al., 2009, British Journal of Nutrition - Health effects of quercetin: from antioxidant to nutraceutical.
Boots, A. W., Haenen, G. R. M. M., and Bast, A., 2008, European Journal of Pharmacology - Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies.
Manach, C., Williamson, G., Morand, C., Scalbert, A., and Rémésy, C., 2005, American Journal of Clinical Nutrition - Flavonoids as antioxidants.
Pietta, P. G., 2000, Journal of Natural Products - Quercetin: A flavonol with multifaceted therapeutic applications?
D'Andrea, G., 2015, Fitoterapia
Research Focus
longevity, senolytic research, cellular senescence, inflammation, oxidative stress, endothelial function, immune signaling, metabolic health
Frequently Asked Questions
What should researchers watch for with Quercetin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Quercetin?
First dose to 24 hours (reported in cited studies): most people notice no acute subjective effect. Mild gastrointestinal upset or headache, if it occurs, is more likely to appear early.
How is Quercetin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →